glp-1 availability Use Has More Than Quadrupled Since 2021 as Obesity Rates Continue to Show Signs of Decline Medicare GLP-1 Drug Coverage -
Description
market. Novo alleged that Hims & Hers has continued to mass compound injectable versions [of Novos Wegovy (semaglutide)] made with inauthentic API and further engaged in promotional campaigns suggesting its compounded semaglutide products compare to the safety and efficacy of Novos Wegovy products putting patient health and wellbeing at risk. Novo further cited FDAs February 6 statement
Switching From Insulin To Ozempic In India: What Actually Happens This is where things get more nuanced, and where Indian-specific data becomes genuinely useful
people on these medications tend to drink less because they curb appetite and dampen reward signals, says Tom Ellis, CEO of Brand Genetics, an innovation consultancy with a special focus on how behavioral science and psychology plays into brand building
Medicare explicitly excludes coverage for weight-loss medications (unless there are associated cardiovascular risks)
